IMMU-140 / Gilead - LARVOL DELTA

Immunomedics announces pricing of public offering of common stock (GlobeNewswire) - "Immunomedics, Inc...announced the pricing of an underwritten public offering of 14,736,860 shares of its common stock at a public offering price of $28.50 per share, representing gross proceeds of approximately $420 million...Immunomedics intends to use the net proceeds from this offering primarily to support the commercial launch of Trodelvy™ in the United States in metastatic triple-negative breast cancer, continue to expand the clinical development programs for Trodelvy, invest in the broader clinical development of the platform (including IMMU-130 and IMMU-140)..."

Financing • Breast Cancer • Oncology • Solid Tumor

Immunomedics Announces Pricing of Public Offering of Common Stock (GlobeNewswire) - "Immunomedics intends to use the net proceeds from this offering primarily to accelerate commercial launch readiness, pending FDA approval, of sacituzumab govitecan in the United States in metastatic triple-negative breast cancer, continue to expand the clinical development programs for sacituzumab govitecan, invest in the broader clinical development of the platform (including IMMU-130 and IMMU-140), continued scale-up of manufacturing and manufacturing process improvements, as well as for working capital and general corporate purposes."

Financing